Alvogen is a global pharmaceutical company focused on developing, manufacturing, and marketing complex, high-value products. The company specializes in inhalation therapies, injectable medications, and strategic 505(b)(2) products, which are new formulations or combinations of existing drugs. Alvogen serves a diverse range of clients, including healthcare providers, hospitals, and pharmacies, primarily in the generic and specialty pharmaceutical markets. The business model revolves around leveraging its extensive R&D capabilities to fuel a growing pipeline of over 50 products currently on the market. Revenue is generated through the sale of these pharmaceutical products, as well as through strategic partnerships and collaborations. Alvogen is committed to quality, cost efficiency, and making a meaningful difference in the lives of patients, aiming to set a new standard in the pharmaceutical industry.

Keywords: pharmaceuticals, inhalation, injectables, 505(b)(2), R&D, healthcare, generics, specialty, quality, cost-efficiency.